Library, OVID and EMBASE databases were searched to identify studies that examined the effect of anaemia on mortality or other adverse events (heart failure, cardiogenic shock or major bleeding). RESULTS: Nineteen studies met the final inclusion criteria (total number of patients 241 293). The risks of shortterm mortality (odds ratio [OR] 2.77; 95% confidence interval [CI] 2.09, 3.65), long-term mortality (OR 2.03; 95% CI 1.52, 2.71), heart failure (OR 1.96; 95% CI 1.47, 2.62), cardiogenic shock (OR 1.95; 95% CI 1.04, 2.64) and major bleeding (OR 4.28; 95% CI 1.05, 17.14) were increased in patients with anaemia, compared with patients without anaemia. Anaemia was also associated with a higher risk of mortality (adjusted hazard ratio 1.49, 95% CI 1.24, 1.79). CONCLUSIONS: These study findings suggest that anaemia can be used to identify patients with ACS who are at a high risk of death or adverse events, and it may become a promising risk stratification factor in ACS. KEY WORDS: ANAEMIA; ACUTE CORONARY SYNDROME; META-ANALYSIS; PROGNOSIS; MORTALITY Y Liu, YM Yang, J Zhu et al. Anaemia and increased mortality in ACS variables. 15 A better understanding of the risk associated with anaemia is, therefore, required. The present meta-analysis was a systematic review of the published literature, in order to summarize the available evidence and estimate the strength of the association between anaemia and adverse outcomes in patients with ACS.
Introduction
The presence of anaemia in heart failure patients (and in patients undergoing cardiac surgery) has been associated with worse clinical outcomes; 1, 2 in addition, an association between anaemia and poor prognosis in patients with acute coronary syndromes (ACS) has been reported in many studies. 3 -11 Anaemia has been shown to be present in 13 -40% of patients presenting with acute myocardial infarction (AMI) or ACS: these patients are at a significant risk of having both baseline anaemia and decreasing haemoglobin (Hb) levels during hospitalization. 4 -12 The mechanisms underlying the more serious outcomes in anaemic patients are not fully understood, but evidence suggests that anaemia may decrease oxygen delivery to the jeopardized myocardium 13 and increase myocardial oxygen demand. 14 Although most studies have documented high mortality rates in anaemic patients with ACS, 4 -10 some have reported an absence of an independent adverse effect, after adjustment for age and other baseline
SEARCH STRATEGY
A systematic search of publications listed in electronic databases (MEDLINE ® via PubMed ® , EMBASE, OVID, The Cochrane Library) between January 1970 and May 2011 was conducted using the following key words, in combination as both MeSH terms and text words: ('acute coronary syndrome' or 'acute myocardial infarction') and ('anaemia' or 'haemoglobin', or 'haematocrit'). Language restrictions were not applied, but the search was limited to human studies. The list of articles was reviewed independently by two authors (Y.L. and Y.M.Y.). In addition, a manual review of references from primary or review articles was performed to identify any additional relevant studies.
STUDY SELECTION
Studies were eligible for inclusion if they met the following criteria: (i) cohort or casecontrol study of patients admitted with AMI or ACS; (ii) reported outcomes (mortality, heart failure, cardiogenic shock or major bleeding) according to the presence of anaemia or Hb/haematocrit (Hct) level. After obtaining full reports of candidate studies, the same reviewers independently assessed eligibility. Differences between the two reviewers were resolved by reviewing corresponding articles, and agreement on the final data set was reached by consensus. If the publications did not contain the full information necessary for a meta-analysis, the missing information was obtained directly from the authors (see Acknowledgements).
QUALITY ASSESSMENT AND DATA ABSTRACTION
Each study was evaluated for quality according to the guidelines provided by the United States Preventive Services Task Force 17 and published recommendations. 18 The following characteristics were assessed: (i) description of patient sample characteristics; (ii) clear inclusion and exclusion criteria; (iii) potential selection bias; (iv) definition of anaemia; (v) a priori definition of study outcomes; (vi) completeness of follow-up; (vii) adjustment of possible confounders in multivariate analysis; (viii) explanation of sample selection; (ix) temporality (Hb measured at baseline, not at time of outcome assessment). Studies were graded as poor quality if they met ≤ 4 criteria, fair if they met 5 -6 criteria, and good if they met ≥ 7 criteria.
For each study, the following data were extracted: first author's last name; publication year; study design; sample size; ACS subtype; baseline characteristics; type of outcome (mortality, heart failure, cardiogenic shock or major bleeding); duration of follow-up; definition of anaemia; variables adjusted for in the multivariate statistical analysis; number of anaemic and nonanaemic patients with outcomes; and, if possible, adjusted mortality hazard ratio (HR) with 95% confidence intervals (CI).
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Collaboration, Oxford, UK) and Stata ® software (version 11.0; Stata Corporation, College Station, TX, USA) were used to pool data for all outcomes. First, unadjusted outcome data (mortality, heart failure, cardiogenic shock or major bleeding) were extracted and pooled to calculate the odds ratio (OR) and 95% CI. The short (in-hospital or 30-day) and long-term (1 -10-year) follow-up cohorts were analysed separately. Secondly, for the studies where adjusted mortality HRs were available, a baseline riskadjusted analysis was performed to determine robustness of results. This was performed because previous studies have found an association between anaemia and characteristics including older age, renal failure, lower left ventricular fraction and lower systolic blood pressure. 3, 5 Heterogeneity was assessed visually using Q (χ 2 ) and I 2 statistics. A random-effect model of DerSimonian and Laird [http:// www.niaid.nih.gov/about/organization/dcr/ BRB/Documents/sdarticle.pdf] was applied to calculate overall differences. Publication bias was estimated using a funnel plot of study results against study precision, with symmetry of the funnel plot assessed by Egger's test. A P-value < 0.05 was considered to be statistically significant.
Results
The initial database search identified 225 studies. Of these, 190 were excluded after scanning the titles and abstracts, leaving 35 studies for detailed review. Full-text assessment resulted in 19 studies that enrolled a total of 241 293 individuals who met the inclusion criteria and were included in the analysis ( Table 1) . 4 -12,15,19 -27 The remaining studies were excluded largely because they included subjects other than ACS patients, they did not examine mortality or other outcomes, or they reported Hb in an unusable format ( Fig. 1) .
The key characteristics of the 19 studies included in the analysis are shown in Table  1 . The association between anaemia and short-term (in-hospital or 30-day) outcomes including mortality, heart failure, cardiogenic shock and major bleeding were reported in 10 studies (mortality data were reported in all studies except Manoukian et al. 22 ); 4,6 -8,10,11,19 -22 six studies reported anaemia and long-term (1 -10-year) mortality; 12,15,23 -26 and three reported both short-and long-term results. 5, 9, 27 All studies were of good or fair methodological quality.
The mean ages of the study cohorts ranged between 59 and 78 years, and the percentages of women ranged between 21% and 54%. The cut-off value for the Hb concentration varied between studies. The World
Health Organization (WHO) definition of anaemia (Hb < 13.0 g/dl for males and Hb < 12.0 g/dl for females) was used in 11 of the included studies. 4, 5, 7, 9, 10, 12, 19, 21, 22, 25, 27 The remaining eight studies divided Hb or Hct concentrations into different categories or quartiles. 6, 8, 11, 15, 20, 23, 24, 26 For the purpose of this analysis, the cut-offs nearest to the WHO definition were used to identify anaemic patients. According to the WHO definition, in the original articles anaemia was present in 24.0% of the ACS patients.
Baseline characteristics and treatments given to the patients with or without anaemia are shown in Table 2 . 4 -12,15,19 -27 As expected, compared with other participants, patients with anaemia were older, more commonly women, had a lower body mass index, a higher Killip class and a higher prevalence of cardiovascular risk factors (including diabetes, hypertension, previous myocardial infarction and higher serum creatinine levels). Anaemic patients were also less likely to be treated with aspirin, Mortality data from 12 short-term studies were pooled (187 441 patients). 4 -11,19 -21,27 Crude analysis of mortality data revealed that 19.4% of anaemic patients died, compared with 9.7% of nonanaemic patients. This translated into an unadjusted short-term mortality risk of OR 2.77 (95% CI 2.09, 3.65) in anaemic patients with ACS ( Fig.  2A ). There was no evidence of publication bias as the funnel plot of all of the short-term studies was not asymmetrical (Egger's test, P = 0.552) (Fig. 2B ). There was significant heterogeneity between the included studies (I 2 = 97%; P < 0.00001).
Mortality data from the nine studies with long-term results were pooled (49 906 patients). 5,9,12,15,23 -27 The incidence of death was 33.2% in patients with anaemia and 21.7% in patients without anaemia. The pooled analysis of these studies showed an association between anaemia and long-term mortality (OR 2.03; 95% CI 1.52, 2.71; Fig.  3 ). Significant heterogeneity between included studies was also observed (I 2 = 95%, P < 0.001). Most studies had a mean length of follow-up between 1 and 3 years, but the study by Valeur et al. 25 had a length of follow-up of 10 years and all patients in this study had left-ventricular systolic dysfunction.
A sensitivity analysis (excluding Valeur et al. 25 ) revealed no appreciable change in the risk of long-term mortality (anaemic versus nonanaemic patients OR 2.15; 95% CI 1.59, 2.92).
The incidence of heart failure in ACS patients was reported in five short-term Duplicate study (n = 1) Anaemia and increased mortality in ACS studies (152 849 patients). 4, 8, 10, 11, 20 Heart failure was seen in 39.0% of anaemic patients compared with 24.1% of nonanaemic patients. Anaemia was associated with a higher risk of heart failure during the in-hospital phase or within 30 days (OR 1.96; 95% CI 1.47, 2.62).
The occurrence of cardiogenic shock was evaluated in four studies (129 136 patients). 4, 7, 11, 19 The incidence of cardiogenic shock in patients with and without anaemia, was 7.9% and 4.8%, respectively. Analysis of these studies showed that anaemic patients had a significantly increased risk of cardiogenic shock (OR 1.95; 95% CI 1.04, 2.64) compared with patients without anaemia.
The incidence of major bleeding was reported in four studies (65 466 patients). 5, 7, 11, 22 Definitions of major bleeding differed between these studies (see footnotes to Table 1 ), but the major bleeding rate was 31.6% in patients with anaemia compared with 3.5% in patients without anaemia. A significantly increased risk of major bleeding was present for anaemic patients (OR 4.28; 95% CI 1.05, 17.45).
The combined risk-adjusted analysis included nine studies (51 449 patients). 5 -7,9,12,15,21,23,27 These studies either used the Cox proportional hazards regression model or a logistic regression model to adjust for known baseline differences between study cohorts. All studies adjusted for age, sex and renal function. Other covariates adjusted for included race, 5,12,15,23 diabetes, 5, 9, 12, 15, 23, 27 hypertension, 5, 15, 21, 23 hypercholesterol aemia, 5, 9 heart failure, 7,23 current smoking, 5,9 prior myocardial infarction, 5, 7, 9, 12, 21, 23 15 Killip class, 5,9 body mass index, 7, 9 ST-elevation on electrocardiogram, 7, 9, 21 infarct location, 7,12,15 bundle branch block, 15 left ventricular dysfunction, 12, 15, 21, 23, 27 major bleeding, 7 increased cardiac enzymes, 21 time from symptom onset to the first balloon inflation, 5 medication, 9, 23 reperfusion therapy 9, 12, 15, 21, 27 and study treatment. 5, 9, 12 Compared with nonanaemic patients, anaemia was associated with a significantly higher risk of adjusted mortality (adjusted HR 1.49; 95% CI 1.24, 1.79; Fig. 4 ). Although adjusting for baseline variables moved the HR toward 1, the results of the risk-adjusted analysis remained statistically significant.
Discussion
This meta-analysis included 241 293 subjects and found that anaemia was present in 24% of ACS patients. The presence of anaemia in 
Anaemia and increased mortality in ACS
ACS patients was associated with an increased short-and long-term risk of mortality as well as an increased incidence of major bleeding, heart failure and cardiogenic shock. This adverse outcome effect was substantial and significant. When assessing the mortality risk by multivariate analysis, anaemia remained an independent risk factor for mortality. This is the first metaanalysis to address the relationship between anaemia and outcomes in patients with ACS.
Several explanations may account for the observed association between anaemia and poor prognosis after ACS. Anaemia may, by itself, confer excess risk; decreased blood oxygen levels may be arrhythmogenic, directly exacerbate myocardial ischaemia, activate the sympathetic nervous system and result in cerebral hypoperfusion. 13, 14, 29, 30 All studies adjusted for age, sex, and renal function. Other covariates adjusted for included race, 5, 12, 15, 23 diabetes, 5, 9, 12, 15, 23, 27 hypertension, 5, 15, 21, 23 hypercholesterolaemia, 5,9 heart failure, 7,23 current smoking, 5,9 prior myocardial infarction, 5, 7, 9, 12, 21, 23 chronic obstructive pulmonary disease, 5, 12, 15 arrhythmia, 15 Killip class, 5,9 body mass index, 7, 9 ST-elevation on electro cardiogram, 7, 9, 21 infarct location, 7, 12, 15 bundle branch block, 15 left ventricular dysfunction, 12, 15, 21, 23, 27 major bleeding, 7 increased cardiac enzymes, 21 time from symptom onset to the first balloon inflation, 5 medication, 9, 23 reperfusion therapy, 9, 12, 15, 21, 27 and study treatment 5, 9, 12 Y Liu, YM Yang, J Zhu et al.
Anaemia was a covariate with other highrisk features known to reduce survival after AMI. Patients with anaemia had an increased frequency of comorbid risk factors such as diabetes, hypertension, previous myocardial infarction and higher serum creatinine levels. These are all factors known to worsen the prognosis after AMI and may, therefore, have confounded the results. 31 -33 After adjusting for a broad array of baseline characteristics, however, anaemia remained an independent predictor of mortality.
Another explanation for the increased mortality is the high risk of bleeding in patients with anaemia. Contemporary intervention (such as antiplatelet treatment, anticoagulants, thrombolytic therapy and invasive procedures) are potential sources for blood loss in patients with ACS. 3, 28 For example, in the study by Al Falluji et al., 15 anaemia was present in 6.4% of patients in 1986 (prethrombolytic era) compared with 10.2% of patients in 1996 (thrombolytic era). Blood loss, whether occult or clinically apparent, was associated with the development or worsening of anaemia. 34 Moreover, patients with anaemia may also present with other predictors of bleeding, such as renal dysfunction, older age, female gender or haemodynamic instability. 35, 36 The present meta-analysis demonstrated that the risk of major bleeding for anaemic patients was significantly higher than that for nonanaemic patients. This is consistent with the REPLACE-2 analysis, which revealed that anaemia in percutaneous coronary intervention patients was associated with a significantly higher rate of protocol-defined major bleeding compared with patients without. 37 Bleeding is currently the most common noncardiac complication of therapy in ACS, which is independently associated with increased mortality and ischaemic events. 37 The problem of anaemia and bleeding complications may become cyclical, leading to increased morbidity and mortality in ACS patients.
Differences in revascularization and pharmacological treatment may also contribute to the worsened prognosis in patients with anaemia. Anaemic patients in the present meta-analysis were less likely to be treated with aspirin, β-blockers and reperfusion therapies (coronary angioplasty or thrombolysis), all of which are known to prolong survival after ACS. The study by Nikolsky et al. 5 found that up to 18% of patients with anaemia after AMI were not receiving aspirin at 1-year follow-up. Moreover, lack of aspirin use remained an independent risk factor for mortality after multivariate analysis. 5 The low use of such beneficial therapies in anaemic patients may be partially attributed to different baseline characteristics (anaemic patients were older and had more contraindications to revascularization procedures compared with nonanaemic patients). It may also be that their increased incidence of preadmission bleeding events (or possible concerns about recurrent bleeding) result in the selection of more conservative strategies. The decreased long-term survival and higher ischaemic complications observed in patients with anaemia after discharge may be partly explained by this undertreatment.
This meta-analysis has several limitations. First, not all studies reported anaemia according to the WHO definition. The definition of anaemia was a major source of heterogeneity and the different cutoff values chosen for Hb/Hct might have introduced bias. In spite of the different definitions of anaemia, the association with outcomes was robust using different analytical strategies. Secondly, nearly all studies included in this analysis (except Alexander et al. 11 and Vaglio et al. 12 ) evaluated the association between baseline anaemia and outcomes. Evidence suggests, however, that the prevalence of anaemia may increase strikingly during hospitalization, and that nadir or discharge Hb perform better as predictors of mortality than the admission Hb value. 24 The prognostic significance of anaemia after hospitalization needs further evaluation. Thirdly, statistical heterogeneities were found when quantitative pooling was performed for some outcomes. In addition to the different definitions of anaemia, other potential explanations for heterogeneity include between-study differences in temporal and local practice patterns, duration of follow-up, patient selection and concomitant therapies. A random-effects model was used in an effort to incorporate heterogeneity between trials in this analysis, but this does not eliminate the fact that heterogeneities were present. Finally, the observational nature of the studies identified provided associative -not causalevidence and mandates caution when interpreting the results.
In conclusion, this systematic review and meta-analysis demonstrated that anaemia was present in 24.0% of the ACS population, and was associated with an increased risk of short-and long-term death, and other adverse outcomes, in these patients. This may be related to haemodynamic changes, higher prevalence of comorbidities, bleeding complications and, possibly, the inappropriate undertreatment of anaemic ACS patients. These findings identify anaemia as a promising tool for risk stratification of patients with ACS.
